Ayman CHEIKH LAHLOU, CEO, Cooper Pharma, presents Apirl 21, 2021, to the mHealth Israel community. Cooper at a Glance: History, DNA & Key Figures. Commitments Towards Quality. Partnerships in Licensing. Cooper Pharma’s vision is to be a leading player in the Healthcare and Pharmaceutical sector at local and regional levels, through a large range of products and services. Make medicines more available to patients by: Producing and marketing branded generic and innovate drugs of the highest quality at the best price. Making all drugs available at any time and everywhere in Morocco. Manufacturing of over 200 specialties in nearly 300 presentations both for its own range of branded generics and on behalf of international pharmaceutical companies. Cooper Pharma focuses part of its strategy on the international market, thus considering exports as a vector of development and competitiveness. Through its wholesale activity with 9 distribution companies across Morocco, Cooper Pharma can provide its citizens with all imported & manufactured drugs with a reduced lead times to pharmacies. Therapeutic areas include GASTROENTEROLOGY, GENERAL MEDICINE & ANTIBIOTHERAPY, WOMEN’S HEALTH, SELF MEDICATION, CLINICS, HOSPITALS & ONCOLOGY, SPECIALTY. THERE IS STILL ROOM FOR IMPROVEMENT TO UPGRADE PATIENT & PHYSICIAN EXPERIENCES IN MOROCCO Further progress could be made. We need to make it happen in short & middle term with long-term realistic targets by leveraging experience from others.

1. DATE XXX
APRIL 12th, 2021
TransTech Health Innovation
Speaker
Ayman CHEIKH LAHLOU
CEO of Cooper Pharma (Morocco, Africa and Middle East)

2. DATE XXX
PRODUCTEUR
DISTRIBUTEUR
EXPORTATEUR
DE
SPÉCIALITÉS
PHARMACEUTIQUES
TABLE OF CONTENTS
1
2
3
4
Cooper at a Glance: History, DNA & Key Figures
Our Commitments Towards Quality
Our Partnerships in Licensing
Cooper Footprint
5 Product Portfolio
6 Cooper Pharma’s Digital Community
7 Cooper Pharma & TransTech Health

3. COOPER PHARMA: NATIONAL PHARMA LEADER
OVER AFRICA & THE MIDDLE EAST

4. DATE XXX
PRODUCTEUR
DISTRIBUTEUR
EXPORTATEUR
DE
SPÉCIALITÉS
PHARMACEUTIQUES
COOPER AT A GLANCE: HISTORY
Founding of Cooper
Maroc, subsidiary of
Cooper Melun France
with imports/
wholesale activity
1933
Launch of
manufacturing
activity
1965
Building of
manufacturing
facility at Tit
Mellil (Morocco)
1980
Launch of
exports
activity
1999
Launch of
Cooper private
label of
branded
generics
2000
ISO 9001
Certification of
manufacturing
facilities
2001
MC Pharma,
Manufacturing plant
in Morocco of
effervescent
products & humidity-
controlled forms
2013
AFSSAPS
Certificate today
ANSM (French
National Security
Agency of
Medicines)
2012
Acquisition of
Rougier OTC
Pharma
company in
Prague, Cz
Republic
2011
Saoudi FDA
Certificate
2010
Creation of IDC
Pharma – R&D
Platform
2008
Founding of
Cooper
International
based in
Dubai, UAE
2007
- CSR Label
- Signature with the
Ivory Coast
government for the
construction of local
manufacturing plant
2014
JV in KSA with SPIMACO
ADDWAEIH: production
of oral forms JV with the
Indian leader CIPLA:
production of
respiratory inhalers in a
dedicated site in
Morocco
2015
Cooper
Pharma East
Africa (Plant
project in
Rwanda)
2016
Pharmax JV for
manufacturing
with IDS and
Bottu (Dubai,
UAE)
2017
Inauguration
of Gynebio
Pharma
(Casablanca),
1st site
dedicated to
hormones
2019
Inauguration of IDC
Pharma
(Casablanca) for
Innovation &
Development
2020
1

5. DATE XXX
PRODUCTEUR
DISTRIBUTEUR
EXPORTATEUR
DE
SPÉCIALITÉS
PHARMACEUTIQUES
OUR MISSION
Make medicines more available to patients by:
 Producing and marketing branded generic and innovate drugs of the highest quality at the best price.
 Making all drugs available at any time and everywhere in Morocco.
COOPER AT A GLANCE: DNA
Strengthen our
Generic Portfolio
Sustain our partnerships with
International Companies
Build tailored cooperation models
adapted to each country in Africa,
the Middle East & Europe.
OUR VISION
Cooper Pharma’s vision aims to:
1
Cooper Pharma’s vision is to be a leading player in the Healthcare and Pharmaceutical sector
at local and regional levels, through our large range of products and services.

6. DATE XXX
PRODUCTEUR
DISTRIBUTEUR
EXPORTATEUR
DE
SPÉCIALITÉS
PHARMACEUTIQUES
COOPER AT A GLANCE: DNA (2)
1
BUSINESS MODEL
MANUFACTURING
Manufacturing of over 200 specialties in nearly 300 presentations both
for its own range of branded generics and on behalf of international
pharmaceutical companies.
EXPORTS
Cooper Pharma focuses part of its strategy on the international market,
thus considering exports as a vector of development and
competitiveness.
DISTRIBUTION
Through its wholesale activity with 9 distribution companies across
Morocco, Cooper Pharma can provide its citizens with all imported &
manufactured drugs with a reduced lead times to pharmacies.
Cooper Pharma’s has a Unique Business Model in Morocco with 3 activities:

7. DATE XXX
PRODUCTEUR
DISTRIBUTEUR
EXPORTATEUR
DE
SPÉCIALITÉS
PHARMACEUTIQUES
RESPECT OF
COMMITMENTS
TRANSPARENCY PROACTIVITY COMMUNITY
ORIENTED
COOPER AT A GLANCE: DNA (3)
1
AT COOPER PHARMA WE ARE CITIZENS BEFORE BEING TEAM MATES. OUR VALUES BRING US TOGETHER.

8. DATE XXX
PRODUCTEUR
DISTRIBUTEUR
EXPORTATEUR
DE
SPÉCIALITÉS
PHARMACEUTIQUES
COOPER AT A GLANCE: KEY FIGURES
9
Distribution Centers
(Wholesale Activity)
9
Manufacturing Plants
Dedicated (owned and JV)
1500
Employees
Including subsidiaries,
local JV and abroad
276
Millions
TOTAL SALES IN 2020
Packs (SKU) manufactured
(Generics 85% + Licensed
15%) in Tit Mellil
42
Millions
12%
Share of Production
Dedicated to exports
(on manufactured
products)
& International Business
1

9. DATE XXX
PRODUCTEUR
DISTRIBUTEUR
EXPORTATEUR
DE
SPÉCIALITÉS
PHARMACEUTIQUES
OUR COMMITMENTS TOWARDS QUALITY
A quality control laboratory that
performs the physico-chemical,
microbiological and stability analysis to
insure a compliant product (60 people
in QA/QC).
A control of all production parameters
to ensure environmental protection.
The raw materials imported from
abroad are meeting the most stringent
quality standards.
Our Quality Certifications
For Cooper Pharma, certification are an integral
part of the strategic vision:
 GMP Certification by the Moroccan Health
Ministry
 ISO 9001 Version 2000 for the quality
Management System, in 2003, renewed in
2006
 The French certification AFSSAPS (today
ANSM : Drug and Health Products Safety
Agency) in 2008
 The Saudi Certification by the Food and Drug
Administration – Saudi FDA in 2011
 The manufacturing Site Registration
Certificate – in 2015 UAE
2

10. DATE XXX
PRODUCTEUR
DISTRIBUTEUR
EXPORTATEUR
DE
SPÉCIALITÉS
PHARMACEUTIQUES
OUR PARTNERSHIPS IN LICENSING
Since 1965, Cooper Pharma produces on behalf of more than c.20 multinational laboratories in 4 continents
with a mixed business model: imports, distribution and local manufacturing.
3

11. DATE XXX
PRODUCTEUR
DISTRIBUTEUR
EXPORTATEUR
DE
SPÉCIALITÉS
PHARMACEUTIQUES
COOPER PHARMA’S SCOPE
“COOPER
IVORY COAST”
“COOPER EAST
AFRICA”
PHARMAX: JV
WITH IDS IN DUBAI
DAMMAN
PHARMA: JV WITH
SPIMACO IN KSA
COOPER
INTERNATIONAL
(DUBAI)
ROUGIER CZ
(PRAGUE)
TIT MELIL UNITS
MC PHARMA
(A SPECIALIZED PLANT IN
EFFERVESCENT
PRODUCTS)
GYNEBIO
PHARMA:
WOMEN HEALTH
(CONTRACEPTIVES &
HORMONES)
Ipharma: JV WITH
SPIMACO IN
MOROCCO
JV WITH CIPLA
(MANUFACTURING OF
MDI: INHALERS/SPRAY)
IDC PHARMA
(INNOVATION
DEVELOPMENT
COOPER)
9 DISTRIBUTION
SUBSIDIARIES
MOROCCO AFRICA
Ivory Coast
Rwanda
EUROPE
UAE
SAUDI ARABIA
MORE TO COME
4

12. DATE XXX
PRODUCTEUR
DISTRIBUTEUR
EXPORTATEUR
DE
SPÉCIALITÉS
PHARMACEUTIQUES
AFRICA, EUROPE & MIDDLE EAST PARTNERSHIPS:
SALES, MARKETING & MANUFACTURING
WEST AFRICA:
 PROMOTION OFFICES 100
MEDICAL REPS
 MANUFACTURING PLANT
IN IVORY COAST (Q4 21)
MOROCCO:
 COOPER TIT MELIL PLANT
 GYNEBIO PLANT
 MC PHARMA PLANT
 CIPLA JV PLANT
 SPIMACO MAROC JV
PLANT
EUROPE:
 CZ REPUBLIC PHARMA COMPANY
(ROUGIER ACQUISITION)
LEVANT:
 DISTRIBUTION DEALS
UAE:
 JV WITH TOP 3 DISTRIBUTOR IN PHARMA
GREENFIELD MANUFACTURING PLANT,
EMA APPROVED
SAUDI ARABIA:
 JV WITH Nº1 SPIMACO IN NEW
GREENFIELD PLANT: DAMMAN PHARMA
 COOPER KSA SCIENTIFIC OFFICE
EAST AFRICA
 START OF COMMERCIAL OPERATIONS
 “COOPER PHARMA EAST AFRICA” PLANT
IN RWANDA (Q4 21)
4

13. DATE XXX
PRODUCTEUR
DISTRIBUTEUR
EXPORTATEUR
DE
SPÉCIALITÉS
PHARMACEUTIQUES
PRODUCTS PORTFOLIO: OUR THERAPEUTIC AREAS
GASTROENTEROLOGY
WOMEN’S HEALTH
(GYNECO/DERMATO)
CLINICS, HOSPITALS &
ONCOLOGY
SELF MEDICATION
(OTC, OTX)
SPECIALTY
(CARDIO/RHUMATO/
UROLOGY/ RESPIRATORY)
GENERAL MEDICINE &
ANTIBIOTHERAPY
5
The product portfolio of Cooper Pharma has nearly 300 presentations in the following therapeutic areas:

14. DATE XXX
PRODUCTEUR
DISTRIBUTEUR
EXPORTATEUR
DE
SPÉCIALITÉS
PHARMACEUTIQUES
PRODUCTS PORTOLIO: OUR BRANDED PRODUCTS
5
Some of our Brands we have built

15. DATE XXX
PRODUCTEUR
DISTRIBUTEUR
EXPORTATEUR
DE
SPÉCIALITÉS
PHARMACEUTIQUES
COOPER PHARMA’S DIGITAL COMMUNITY
+144,000
FANS
SOCIAL MEDIA THE PRESS: THEY ARE TALKING ABOUT US!
+52,000
SUBSCRIBERS
Between 100 & 10 000
likes per post
#Cooper stories #Health advice
“Cooper Pharma contribue
pour 20 MDH au Fonds spécial
anti-Covid-19”
“Cooper Pharma regional
player in Africa & Middle-East
strengthens ties with American
pharmaceutical”.
6
15.01.2020
13.04.2020
27.10.2020

16. OPPORTUNITIES FOR COLLABORATION
FRANCE - MOROCCO - ISRAEL

17. DATE XXX
PRODUCTEUR
DISTRIBUTEUR
EXPORTATEUR
DE
SPÉCIALITÉS
PHARMACEUTIQUES
‘
THERE IS STILL ROOM FOR IMPROVEMENT TO UPGRADE
PATIENT & PHYSICIAN EXPERIENCES IN MOROCCO
Further progress could be made. We need to make it happen in short & middle term with
long-term realistic targets by leveraging experience from others.
7
E-HEALTH
 How to develop and implement Digital and Data-Driven solutions in the Moroccan Healthcare System?
RESEARCH & DEVELOPMENT
 How to better use R&D (ex. Biotechnology) and innovation in the Moroccan Health system?
DISPARITIES
 How to bridge the gap between urban and rural populations access to health care ?
 How to improve the quality of services for a better social equity ? 20% of the population lives more than 10
km from hospitals
HUMAN RESOURCES
 How to address the shortage of ad-hoc and trained medical personnel ? How to improve working
conditions ?
INFRASTRUCTURES
 How to support the generalization of access to health care through a review of hospitals infrastructures ?

18. DATE XXX
PRODUCTEUR
DISTRIBUTEUR
EXPORTATEUR
DE
SPÉCIALITÉS
PHARMACEUTIQUES
COOPER PHARMA & TRANSTECH HEALTH INNOVATION
TransTech Health
Innovation
&
E-HEALTH & TELEMEDICINE
• Online & remote consultations
• Biomedical technologies & data-driven solutions
(wearable devices, health data tracking…)
IN-LICENSING OF INNOVATIVE PRODUCTS
• BioTech
• Vaccines
• CRISPR Tech in diagnostics
PROFESSIONAL TRAINING OF HEALTH WORKERS
• Continuing education for Doctors
• Nurses schools
• Adhoc needs
Cooper Pharma aims to address the Moroccan challenges in Mobile Health, Products Innovation and Professional
Trainings by exploring partnership opportunities with French and Israeli companies and allowing them to leverage
on Morocco as a hub to Africa and the Middle East.
7

19. DATE XXX
PRODUCTEUR
DISTRIBUTEUR
EXPORTATEUR
DE
SPÉCIALITÉS
PHARMACEUTIQUES

20. APPENDIX

21. DATE XXX
PRODUCTEUR
DISTRIBUTEUR
EXPORTATEUR
DE
SPÉCIALITÉS
PHARMACEUTIQUES
“Cooper Pharma, regional player in
Africa & Middle-East strengthens ties
with American pharmaceutical”
MR. AYMAN CHEIKH LAHLOU, CEO OF COOPER PHARMA